Dr Marc P. Bonaca, MD, MPH, FAHA, FACC

Executive Director, CPC
William R. Hiatt Endowed Chair in Cardiovascular Research
Professor of Medicine, Cardiology & Vascular Medicine
Director of Vascular Research
University of Colorado School of Medicine

Marc P. Bonaca, MD, MPH, FAHA, FACC is a cardiologist and vascular medicine specialist who serves as the executive director of CPC Clinical Research and Community Health, as well as Director of Vascular Research and Professor of Medicine at the University of Colorado Anschutz Medical Campus.

Dr. Bonaca earned his medical degree from the University of Connecticut School of Medicine and his master’s in public health at Harvard University. He completed his medical residency, cardiology fellowship, and fellowship in vascular medicine at Brigham and Women’s Hospital as well as a dedicated research fellowship at the TIMI Study Group.

After completion of his training, he joined the faculty at Brigham and Women’s Hospital and Harvard Medical School and became an investigator at the TIMI Study Group. He directed pharmacovigilance at TIMI and worked as an investigator on a number of large outcomes trials including TRA2P-TIMI 50, PEGASUS-TIMI 54, DECLARE-TIMI 58, and REAL TIMI 63B. He remains faculty at BWH and is currently Center Director and clinical project principal investigator of the Brigham and Women’s Hospital and Dartmouth Hitchcock Center in the American Heart Association Strategically Focused Research Network in peripheral vascular disease.

In 2018 he joined the faculty at the University of Colorado School of Medicine where is a Professor of Medicine and holds the William R. Hiatt Endowed Chair in Cardiovascular Research. He serves as the Executive Director of CPC Clinical Research, an affiliated non-profit Academic Research Organization. At CPC he has led several clinical trials where CPC has been the lead ARO including VOYAGER PAD, PREVENT HD, and ASPEN and is leading several ongoing trials including BRIGHT and EVOLVE MI, a 4000 patient pragmatic multinational acute coronary syndrome trial. In addition to his work at CPC he serves on the Executive Committees of several large development programs including VICTORION 1 Prevention trial, the Bayer Asundexian Factor XI  program, and the Faraday IOCYTE MI trial. He also serves on the steering committees of the VASALEIUS trial, and is the US National Lead Investigator for the AEGIS II and Merck oral PCSK9i trials.

Dr. Bonaca’s research focus is on ischemic risk in patients with risk factors for or established atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. He has extensive experience in the design and conduct of large, multicenter randomized clinical trials, as well as analyses in registries and real-world datasets. His key areas of interest include patients with peripheral artery disease, polyvascular disease, and diabetes, with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications, and major adverse cardiovascular events. In addition, he is actively investigating the cardiac, vascular, and thrombotic complications associated with novel oncologic therapies. His focus at CPC has been to build a robust faculty and operational group with a focus on high quality, efficient, trials leveraging health networks, informatics, and decentralized design.